__NUXT_JSONP__("/drugs/Lexatumumab", (function(a,b,c){return {data:[{drug:{slug:a,emaEpar:[],fdaDrugLabel:[],id:a,nciThesaurus:{casRegistry:"845816-02-6",chebiId:b,chemicalFormula:b,definition:"A fully human monoclonal agonistic antibody directed against tumor necrosis factor-alpha (TNF-alpha)-related apoptosis-inducing ligand receptor-2 (TRAIL-R2) with potential antitumor activity. Mimicking the natural ligand TRAIL, lexatumumab binds to and activates TRAIL-R2, which may trigger apoptosis in and inhibit the growth of TRAIL-R2-expressing tumor cells. TRAIL-R2, also known as death receptor 5 (DR5), is a member of the TNF receptor family and is expressed on many malignant cell types.",fdaUniiCode:"967Q0SJD77",identifier:"C64621",preferredName:a,semanticType:"Amino Acid, Peptide, or Protein",subclassOf:["C129822","C20401"],synonyms:["Anti-TRAIL Receptor 2 Monoclonal Antibody HGS-ETR2","HGS-ETR2","HGS1018","LEXATUMUMAB",a,"Monoclonal Antibody HGS-ETR2","anti-TRAIL R2 mAb HGS-ETR2","lexatumumab"]},dir:"\u002Fdrugs",path:"\u002Fdrugs\u002FLexatumumab",extension:".json",createdAt:c,updatedAt:c}}],fetch:{},mutations:void 0}}("Lexatumumab","","2021-10-30T13:42:30.783Z")));